NextCure, Inc. (NXTC) Investor Relations Documents

NextCure, Inc. (NXTC) investor relations documents from the company's IR site: 1 presentation, 32 press releases; latest deck 2026-06-01. Read in-app with summaries. First-party data.

View the Virtual KOL Event Slides: SIM0505 Phase 1 trial shows 55% ORR in gynecologic cancers, with 52.9% in ovarian and 66.7% in USC at therapeutic doses.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseNextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-07-14Press releaseNextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
2026-06-04Press releaseNXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SI
2026-06-01PresentationView the Virtual KOL Event Slides
2026-06-01Press releaseNextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
2026-05-07Press releaseNextCure Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-04Press releaseNextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
2026-04-21Press releaseNextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
2026-04-07Press releaseNextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
2026-03-31Press releaseNextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
2026-03-05Press releaseNextCure Provides Business Update and Reports Full Year 2025 Financial Results
2024-11-07Press releaseNextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
2024-08-01Press releaseNextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
2024-05-02Press releaseNextCure Provides Business Update and Reports First Quarter 2024 Financial Results
2024-03-21Press releaseNextCure Provides Business Update and Reports Full Year 2023 Financial Results
2023-11-02Press releaseNextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-08-03Press releaseNextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-05-04Press releaseNextCure Provides Business Update and Reports First Quarter 2023 Financial Results
2023-03-02Press releaseNextCure Provides Business Update and Reports Full Year 2022 Financial Results
2022-11-03Press releaseNextCure Provides Update and Reports Third Quarter 2022 Financial Results
2022-08-04Press releaseNextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
2022-05-05Press releaseNextCure Provides Business Update and Reports First Quarter 2022 Financial Results
2022-03-03Press releaseNextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2021-11-04Press releaseNextCure Reports Third Quarter 2021 Financial Results and Provides Business Update
2021-11-01Press releaseNextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021
2021-08-05Press releaseNextCure Reports Second Quarter 2021 Financial Results
2021-03-04Press releaseNextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
2021-03-02Press releaseREMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021
2021-02-26Press releaseNextCure to Host Virtual R&D Update Event on March 4, 2021
2020-11-05Press releaseNextCure Reports Third Quarter 2020 Financial Results
2020-08-06Press releaseNextCure Reports Second Quarter 2020 Financial Results
2020-05-07Press releaseNextCure Reports First Quarter 2020 Financial Results
Press releaseNextCure Reports First Quarter 2021 Financial Results

NXTC overview · NXTC earnings · NXTC financials · NXTC KPIs · NXTC ownership · NXTC peers · NXTC filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.